<< Back
Urigen Overview of IC/Painful Bladder Syndrome for IC Awareness Week

SAN FRANCISCO--(BUSINESS WIRE)--Oct. 27, 2009-- Urigen Pharmaceuticals, Inc. (OTCBB:URGP), focused on the development of treatments for urologic disorders and pain, announces a presentation at its offices on October 30, 2009 at 2PM PST. The slides presented will be posted to its website at www.urigen.com after the close of trading that day.

“Interstitial Cystitis/Painful Bladder Syndrome is an important unmet medical need,” said Urigen CEO William J. Garner, MD. “As part of IC Awareness Week, Urigen would like to do its part to offer a presentation based on the work of its scientific founder, Lowell Parsons, MD.”

About Urigen Pharmaceuticals, Inc.

Urigen Pharmaceuticals, Inc. is a specialty pharmaceutical company dedicated to the development and commercialization of therapeutic products for urological disorders. Urigen's two lead programs target significant unmet medical needs and major market opportunities in urology. Urigen's URG101, a proprietary combination of approved drugs that is instilled into the bladder, targets painful bladder syndrome, which affects approximately 10.5 million men and women in North America. Urigen's URG301, a proprietary dosage form of an approved drug that is locally delivered to control urinary urgency, targets acute urgency in females diagnosed with an overactive bladder, another major unmet need that is insufficiently managed by presently available overactive bladder drugs. For further information, please visit Urigen's website at http://www.urigen.com.

Forward-Looking Statement

This press release may contain forward-looking statements. These statements may be identified by the use of forward-looking terminology such as "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "might," "plan," "potential," "predict," "should," or "will," or the negative thereof or other variations thereon or comparable terminology. Urigen has based these forward-looking statements on current expectations, assumptions, estimates and projections. While Urigen believes that these expectations, assumptions, estimates and projections are reasonable, such forward-looking statements are only predictions and involve known and unknown risks and uncertainties, many of which are beyond its control. Given these risks and uncertainties, investors and security holders are cautioned not to place undue reliance on such forward-looking statements. Urigen does not undertake any obligation to update any such statements or to publicly announce the results of any revisions to any such statements to reflect future events or developments.

Source: Urigen Pharmaceuticals, Inc.

Urigen Pharmaceuticals, Inc.
Martin E. Shmagin, CFO, 415-781-0350

Could not find file '\\aws.nasdaqomx.com\irweb\content3\IRXMLDATA\92\92144\Disclaimers.xml'.